Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 12 July 2017

FIT Biotech Oy: FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA)

FIT Biotech Oy    

Published: 15:00 CEST 12-07-2017 /GlobeNewswire /Source: FIT Biotech Oy / : FITBIO /ISIN: FI4000148606

FIT Biotech Oy: FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA)

FIT Biotech Oy 

 

Company release 12 July, 2017 at 4:00 PM EET

 

FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA)

FIT Biotech Oy ("Company") has received today a EUR 644,868 payment from its HIV collaborator, the European HIV Vaccine Alliance (EHVA).  The payment was received as part of the contracted scheduled payments for manufacturing the Company's investigational DNA-based HIV vaccine for a large multicenter Phase I/2 clinical trial planned to initiate later this year.  EHVA is financed by the Horizon 2020 program of the European Commission.

FIT Biotech manufactures the investigational DNA-based HIV vaccine for EHVA in its own GMP production facility in Tampere, Finland, that is approved by the Finnish Medicines Agency (Fimea). This facility has the capacity to produce investigational drugs up to Phase 2 clinical trials, thus ensuring a rapid capability to introduce new DNA-based drug candidates to clinical trials.

FIT BIOTECH OY

Further information:
James Kuo
CEO
FIT Biotech Oy
Tel: +1 858 220 5703
E-mail: james.kuo@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

 

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: FIT Biotech Oy, Biokatu 8, Tampere FI-33520, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.